Analytical Data
-
Gene name
ERG11
- Application
-
Alternative Names
ERG11；cyp51；Lanosterol 14-alpha demethylase erg11
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P10614
-
Expression Region
1-20aa
-
AA Sequence
MSATKSIVGEALEYVNIGLS
-
Molecular Weight
29.1 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ERG11, also known as cytochrome P450 51 (CYP51), is a key enzyme involved in the biosynthesis of ergosterol, a crucial component of fungal cell membranes. This protein has gained significant attention in the field of medical mycology and pharmacology, primarily due to its role in conferring resistance to antifungal agents, particularly azoles, which inhibit ergosterol synthesis. The emergence of azole-resistant fungal strains has become a pressing public health concern, necessitating a deeper understanding of ERG11's structure, function, and mutation patterns. Research into the recombinant expression of ERG11 allows for the detailed study of its enzymatic activity and interaction with antifungal drugs. By producing ERG11 in a controlled laboratory setting, researchers can investigate how specific mutations in the ERG11 gene contribute to resistance mechanisms, aiding the development of new therapeutic strategies. Furthermore, characterizing the biochemical pathways regulated by ERG11 can help identify potential drug targets. Overall, the study of ERG11 at a molecular level is critical for advancing our understanding of fungal pathogenesis and developing effective treatments against resistant strains.
